NASDAQ:FLKS Flex Pharma (FLKS) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free FLKS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.49▼$0.5350-Day Range$0.57▼$14.5152-Week Range$0.26▼$1.49Volume20,106 shsAverage Volume2.03 million shsMarket Capitalization$9.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Flex Pharma alerts: Email Address Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Flex Pharma Stock (NASDAQ:FLKS)Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.Read More Ad Crypto Swap ProfitsDid You Get Your Free Bitcoin Yet?And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here FLKS Stock News HeadlinesApril 4, 2024 | seekingalpha.comFlex Ltd.: Undervalued With Solid FundamentalsNovember 17, 2023 | seekingalpha.comFLEX LNG Ltd. 2023 Q3 - Results - Earnings Call PresentationMay 6, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)October 30, 2023 | msn.comUnforgettable Patients: A guy came to the ER for a scratch on his neck and "feeling drowsy." As we start the routine workups, he suddenly drops dead. Days later, his autopsy ...September 4, 2023 | msn.comANGLE release Portrait Flex CTC assaySeptember 1, 2023 | msn.comWhy flex work is as important as pay for someJune 3, 2023 | news.yahoo.com22-year-old woman arrested in Forks after threatening homeowner with gunMay 24, 2023 | fool.comFlex (NASDAQ: FLEX)May 6, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)March 28, 2023 | wsj.comFlex Ltd.March 25, 2023 | forbes.comThat's All Folks: Why the Writing Is on the Wall at MicrosoftMarch 24, 2023 | bbc.co.ukFolk Club with Lynette FayMarch 10, 2023 | msn.comCalifornia flexed its muscle on abortion rights. Will more states and businesses follow?December 12, 2022 | news.yahoo.comCompany to add new flex work space to ShelbySeptember 7, 2022 | finance.yahoo.comOptimal Flex Plays: We are back baby!August 11, 2022 | seekingalpha.comOncoCyte Corporation (OCX) CEO Ronnie Andrews on Q2 2022 Results - Earnings Call TranscriptJune 16, 2022 | seekingalpha.comThe Kraft Heinz Company's (KHC) Management Presents at Deutsche Bank Annual dbAccess Global Consumer Conference (Transcript)June 15, 2022 | seekingalpha.comThe Kraft Heinz Company (KHC) Presents at Deutsche Bank Annual dbAccess Global Consumer Conference (Transcript)June 8, 2022 | finance.yahoo.comOver 500+ Weight Loss Smoothie Recipes Revealed By Cocinaré For Their New Gopower eLite Personal Portable Blender LaunchMay 21, 2022 | dailymail.co.ukMonkeypox is now spotted in Italy and Sweden — bringing number of countries with confirmed or suspected cases to SEVENMay 20, 2022 | msn.comMy Fair Lady, The Breach and Rambert: The best of the week’s live reviewsMay 16, 2022 | seekingalpha.comGinkgo Bioworks Holdings, Inc. (DNA) CEO Jason Kelly on Q1 2022 Results - Earnings Call TranscriptMay 14, 2022 | seekingalpha.comZymergen, Inc. (ZY) CEO Jay Flatley on Q1 2022 Results - Earnings Call TranscriptMay 5, 2022 | seekingalpha.comBecton, Dickinson and Company (BDX) CEO Thomas Polen on Q2 2022 Results - Earnings Call TranscriptApril 14, 2022 | ca.finance.yahoo.comToyota's first EV will start at $42,000March 6, 2022 | yahoo.comBiden May Extend Pause On Student Loan Payments Again: Top AideJanuary 31, 2022 | msn.comFord F-150, Chevy Silverado, Ram 3500 Flex Some Muscle In Tug Of WarSee More Headlines Receive FLKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2019Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:FLKS CUSIPN/A CIK1615219 Webwww.flex-pharma.com Phone617-874-1821FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,920,000.00 Net Margins-1,208.42% Pretax MarginN/A Return on Equity-98.04% Return on Assets-83.37% Debt Debt-to-Equity RatioN/A Current Ratio6.86 Quick Ratio6.74 Sales & Book Value Annual Sales$840,000.00 Price / Sales10.78 Cash FlowN/A Price / Cash FlowN/A Book Value$0.51 per share Price / Book0.98Miscellaneous Outstanding Shares18,070,000Free FloatN/AMarket Cap$9.05 million OptionableNot Optionable Beta1.65 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. William K. McVicar (Age 61)Pres, CEO & Director Dr. Roderick MacKinnon (Age 63)Co-Founder & Co-Chair of Scientific Advisory Board Mr. John McCabe (Age 49)CFO, Treasurer & Sec. Dr. Thomas C. Wessel (Age 63)Outside Advisor Dr. Bruce BeanCo-Founder, Co-Chair of Scientific Advisory Board & Board ObserverKey CompetitorsGraybug VisionNASDAQ:GRAYUniverse PharmaceuticalsNYSE:UPCVirios TherapeuticsNASDAQ:VIRIBiofronteraNASDAQ:BFRIeFFECTOR TherapeuticsNASDAQ:EFTRView All Competitors FLKS Stock Analysis - Frequently Asked Questions How were Flex Pharma's earnings last quarter? Flex Pharma Inc (NASDAQ:FLKS) posted its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.12) earnings per share for the quarter. The biotechnology company earned $0.11 million during the quarter. Flex Pharma had a negative trailing twelve-month return on equity of 98.04% and a negative net margin of 1,208.42%. What other stocks do shareholders of Flex Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Flex Pharma investors own include Ocular Therapeutix (OCUL), Micron Technology (MU), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), Gilead Sciences (GILD), Histogenics (HSGX), TG Therapeutics (TGTX), TherapeuticsMD (TXMD), Celldex Therapeutics (CLDX) and Melinta Therapeutics (MLNT). When did Flex Pharma IPO? Flex Pharma (FLKS) raised $60 million in an IPO on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers. This page (NASDAQ:FLKS) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsDollar CancelledLear CapitalRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupGold Set to EXPLODE!Gold Safe ExchangeThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Flex Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
